You have read all your free articles, to continue reading subscribe to read the rest of this content.
BioArctic has announced that the company’s partner AbbVie has decided to terminate its collaboration with BioArctic regarding the portfolio of alpha-synuclein antibodies, including ABBV-0805. BioArctic and AbbVie have collaborated since 2016 regarding the research and development of BioArctic'sAlready a subscriber Login You have read all your free articles, to continue…
A first-of-its kind comparison of the business risks confronting six key European industries revealed that the biopharmaceutical sector faces the highest level of risk and economic uncertainty. The study conducted by Deloitte and commissioned by Janssen, compared six industry sectors: the biophAlready a subscriber Login You have read all your…
NeuroVive Pharmaceutical and Yungjin Pharm Corporation have entered into a global licensing agreement on Yungjin Pharm's compound KL1333 for genetic mitochondrial disorders. The in-licensed project is about to enter Phase I clinical development. KL1333 is a drug intended for treatment of orphaAlready a subscriber Login You have read all your…
AstraZeneca has entered into an agreement with TerSera Therapeutics (TerSera) for the commercial rights to Zoladex (goserelin acetate implant) in the US and Canada. Zoladex is an injectable luteinising hormone-releasing hormone agonist, used to treat prostate cancer, breast cancer and certain benAlready a subscriber Login You have read all your…
